NCT06389695Recruiting
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of a Single Dose of Gallium [68Ga]-NYM032 Injection Prepared by Kit for the Preparation of the 68Ga-NYM032 Injection in Patients With Prostate Cancer
Norroy Bioscience Co., LTDPhase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Prostate Cancer
- Drug/Device/Intervention
- 68Ga-NYM032 injection
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Norroy Bioscience Co., LTD
- Location
- Wuxi, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- May 01, 2024
- End date
- Dec 01, 2024
- Enrollment
- 10 participants
Primary outcome
Incidence of Adverse Events
Summary
68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate
 cancer, which is needed for clinical trial to be conducted
ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06389695
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06389695 through Pure Global AI's free database. This Phase 1 trial is sponsored by Norroy Bioscience Co., LTD and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.